NETs Get Real with NCAN The Truth about PRRT with Dr. Aman Chauhan
Jun 26, 2024
Dr. Aman Chauhan, a leading medical oncologist at the University of Miami, discusses the groundbreaking Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors. He delves into how PRRT works, its advantages and potential challenges for patients. Success stories underscore the therapy's importance, while the discussion on theranostics highlights its precision in targeted cancer treatment. Listeners are encouraged to access resources that enhance their understanding of neuroendocrine tumors and engage with ongoing education around this critical topic.
AI Snips
Chapters
Transcript
Episode notes
PRRT's Targeted Radiation Approach
- PRRT uses a radioactive drug attached to a somatostatin analog to precisely target neuroendocrine tumor cells.
- This theranostic approach enables effective radiation delivery to tumors while sparing normal tissues like kidneys and bone marrow.
PRRT Proven Effective and Well-Tolerated
- A key study showed PRRT extended progression-free survival from about 8 to nearly 30 months compared to high-dose somatostatin analog.
- PRRT also improved patients' quality of life, unlike many cancer treatments that cause debilitating side effects.
When to Consider PRRT Treatment
- Consider PRRT for diffuse metastatic disease, especially with bone involvement and symptomatic pain.
- Use PRRT for progressive neuroendocrine tumors beyond liver or when disease needs cytoreduction in functional tumors not eligible for surgery.